Fausto Salaffi1, Valeria Giorgi2, Silvia Sirotti3, Sara Bongiovanni3, Sonia Farah1, Laura Bazzichi4, Daniela Marotto5, Fabiola Atzeni6, Maurizio Rizzi7, Alberto Batticciotto8, Giovanni Lombardi9, Massimo Galli10, Piercarlo Sarzi-Puttini3. 1. Rheumatology Unit, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy. 2. Rheumatology Unit, ASST Fatebenefratelli-Luigi Sacco University Hospital, Milan, Italy. vale.gio@fastwebnet.it. 3. Rheumatology Unit, ASST Fatebenefratelli-Luigi Sacco University Hospital, Milan, Italy. 4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. 5. Rheumatology Unit, ATS Sardegna, P. Dettori Hospital, Tempio Pausania, Italy. 6. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Italy. 7. Respiratory Unit, L. Sacco University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy. 8. Rheumatology Unit, Internal Medicine Department, ASST Settelaghi, Ospedale Di Circolo - Fondazione Macchi, Varese, Italy. 9. Laboratory of Experimental Biochemistry & Molecular Biology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy, and Department of Athletics, Strength and Conditioning, Poznań University of Physical Education, Poznań, Poland. 10. Department of Infectious Diseases, ASST-Fatebenefratelli-Luigi Sacco University Hospital, Department of Biochemical and Clinical Sciences "L. Sacco", University of Milan, Italy.
Abstract
OBJECTIVES: Fibromyalgia syndrome (FM) is a complex disease that is mainly characterised by chronic widespread pain, fatigue and sleep disturbances and may be precipitated or worsened by many stressors. The aim of this study was to observe the behaviour of FM symptoms during the course of coronavirus disease 2019 (COVID-19). METHODS: Patients who had been diagnosed as having FM for ≥3 months were recruited between February and May 2020. The collected data were age, sex, educational level and marital status; height and weight; and the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromyalgia Assessment Status 2019 (FASmod), and the Polysymptomatic Distress Scale (PDS). The patients were divided into those with or without concomitant COVID-19 infection. RESULTS: Eight hundred and ninety-seven (93%) of the 965 patients (881 women [91.3%] and 84 men [8.7%]) were followed up on an outpatient basis because of FM and 68 (7.0%) were either followed up as out-patients or hospitalised because of COVID-19. There was no difference in the sociodemographic data of the two groups, but there were statistically significant between-group differences in the results of the clinimetric tests. The major differences between the score of the items (those with the greatest disease impact) were the following related symptoms: sleep quality (FIQR15), fatigue/energy (FIQR13), pain (FIQR12), stiffness (FIQR14). CONCLUSIONS: The mean total and subdomain scores of all the tests were significantly higher in the patients with COVID-19, which suggests that global FM symptoms are more severe in patients with infection. Further studies of the post-COVID19 patients are being carried out in order to discover whether the worsened symptomatology continues because of their hypersensitised state.
OBJECTIVES: Fibromyalgia syndrome (FM) is a complex disease that is mainly characterised by chronic widespread pain, fatigue and sleep disturbances and may be precipitated or worsened by many stressors. The aim of this study was to observe the behaviour of FM symptoms during the course of coronavirus disease 2019 (COVID-19). METHODS: Patients who had been diagnosed as having FM for ≥3 months were recruited between February and May 2020. The collected data were age, sex, educational level and marital status; height and weight; and the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromyalgia Assessment Status 2019 (FASmod), and the Polysymptomatic Distress Scale (PDS). The patients were divided into those with or without concomitant COVID-19 infection. RESULTS: Eight hundred and ninety-seven (93%) of the 965 patients (881 women [91.3%] and 84 men [8.7%]) were followed up on an outpatient basis because of FM and 68 (7.0%) were either followed up as out-patients or hospitalised because of COVID-19. There was no difference in the sociodemographic data of the two groups, but there were statistically significant between-group differences in the results of the clinimetric tests. The major differences between the score of the items (those with the greatest disease impact) were the following related symptoms: sleep quality (FIQR15), fatigue/energy (FIQR13), pain (FIQR12), stiffness (FIQR14). CONCLUSIONS: The mean total and subdomain scores of all the tests were significantly higher in the patients with COVID-19, which suggests that global FM symptoms are more severe in patients with infection. Further studies of the post-COVID19 patients are being carried out in order to discover whether the worsened symptomatology continues because of their hypersensitised state.
Authors: Javier Rivera; Tamara Rodríguez; Marta Pallarés; Isabel Castrejón; Teresa González; Laura Vallejo-Slocker; Juan Molina-Collada; Fernando Montero; Anna Arias; Miguel A Vallejo; Jose M Alvaro-Gracia; Antonio Collado Journal: BMC Musculoskelet Disord Date: 2022-05-19 Impact factor: 2.562
Authors: Zoltán Szekanecz; Attila Balog; Tamás Constantin; László Czirják; Pál Géher; László Kovács; Gábor Kumánovics; György Nagy; Éva Rákóczi; Szilvia Szamosi; Gabriella Szűcs; István Vályi-Nagy Journal: Expert Rev Mol Med Date: 2022-03-15 Impact factor: 5.600
Authors: Teresa Paolucci; Alessandro de Sire; Martina Ferrillo; Dania di Fabio; Aurora Molluso; Antonia Patruno; Mirko Pesce; Carlo Lai; Chiara Ciacchella; Aristide Saggino; Francesco Agostini; Marco Tommasi Journal: Front Physiol Date: 2022-08-26 Impact factor: 4.755
Authors: María Dolores Hinchado; Eduardo Otero; María Del Carmen Navarro; Leticia Martín-Cordero; Isabel Gálvez; Eduardo Ortega Journal: J Clin Med Date: 2022-09-28 Impact factor: 4.964